Weiss & Lurie, a national class action and shareholder rights law firm with offices in New York City and Los Angeles, is investigating possible breaches of fiduciary duty and other violations of law by members of the Board of Directors of Cypress Bioscience, Inc. (NASDAQ: CYPB) arising from the proposed acquisition of Cypress by Ramius V&O Acquisition LLC and Royalty Pharma.

Under the terms of the transaction, Cypress shareholders will receive $6.50 for each share of Cypress. The value of the transaction is approximately $255 million and is expected to close in January 2011, but could close as early as December 30, 2010.

Weiss & Lurie is investigating whether Cypress’ Board acted in the best interests of shareholders in approving the transaction and whether proper disclosure has been made to Cypress’ shareholders.

If you own Cypress common stock and would like more information about your rights as a shareholder or additional information concerning our investigation, please contact Michael A. Rogovin either by email at infony@weisslurie.com or by telephone at (888) 593-4771.

Weiss & Lurie has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded institutions and individuals and obtained important corporate governance in these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (such as insider trading, waste of corporate assets, accounting fraud, or issuing materially misleading press releases or SEC filings), consumer fraud (such as false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at infony@weisslurie.com or fill out the form on our website, http://www.weisslurie.com/contact/report_fraud/.

Attorney Advertising. Past results do not guarantee a similar outcome.

Cypress Bioscience (NASDAQ:CYPB)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Cypress Bioscience Charts.
Cypress Bioscience (NASDAQ:CYPB)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Cypress Bioscience Charts.